Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients

Jong Baeck Lim, Oh Hun Kwon, Hyon Suk Kim, Hyun Ok Kim, Jong Rak Choi, Maurizio Provenzano, David Stroncek

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) reactivation in immune compromised patients such as those undergoing hematopoietic progenitor cell transplantation (HPCT) and those with HIV infections can cause severe morbidity and mortality despite treatment with appropriate antiviral agents. The recovery of Cytomegalovirus (CW) specific cytotoxic T lymphocytes (CTL) plays an important role in the reconstitution of CMV specific immunity in immunocompromised patients. Recent studies have reported that CMV reactivation can be successfully treated by adoptive transfer of CW-specific T cell clones from CMV seropositive donors expanded in vitro with CMV infected fibroblasts or lysates of CMV infected cells. Other studies have used immune dominant CMV proteins or peptides to expand CMV-specific cytotoxic T lymphocytes. This review describes the clinical manifestations of CMV disease in immunocompromised patients, recent advances of antiviral therapy for CMV disease, the principals of the induction of cellular immune response to CMV, and the clinical application of CMV immunotherapy.

Original languageEnglish
Pages (from-to)18-22
Number of pages5
JournalYonsei medical journal
Volume45
Issue numberSUPPL.
Publication statusPublished - 2004 Jun 30

Fingerprint

Adoptive Immunotherapy
Immunocompromised Host
Cytomegalovirus
Cytotoxic T-Lymphocytes
Antiviral Agents
Adoptive Transfer
Cell Transplantation
Hematopoietic Stem Cells
Cellular Immunity
Immunotherapy
HIV Infections

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lim, J. B., Kwon, O. H., Kim, H. S., Kim, H. O., Choi, J. R., Provenzano, M., & Stroncek, D. (2004). Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients. Yonsei medical journal, 45(SUPPL.), 18-22.
Lim, Jong Baeck ; Kwon, Oh Hun ; Kim, Hyon Suk ; Kim, Hyun Ok ; Choi, Jong Rak ; Provenzano, Maurizio ; Stroncek, David. / Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients. In: Yonsei medical journal. 2004 ; Vol. 45, No. SUPPL. pp. 18-22.
@article{fb9bf528b3a846c1bcdb7d7c59cc771b,
title = "Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients",
abstract = "Cytomegalovirus (CMV) reactivation in immune compromised patients such as those undergoing hematopoietic progenitor cell transplantation (HPCT) and those with HIV infections can cause severe morbidity and mortality despite treatment with appropriate antiviral agents. The recovery of Cytomegalovirus (CW) specific cytotoxic T lymphocytes (CTL) plays an important role in the reconstitution of CMV specific immunity in immunocompromised patients. Recent studies have reported that CMV reactivation can be successfully treated by adoptive transfer of CW-specific T cell clones from CMV seropositive donors expanded in vitro with CMV infected fibroblasts or lysates of CMV infected cells. Other studies have used immune dominant CMV proteins or peptides to expand CMV-specific cytotoxic T lymphocytes. This review describes the clinical manifestations of CMV disease in immunocompromised patients, recent advances of antiviral therapy for CMV disease, the principals of the induction of cellular immune response to CMV, and the clinical application of CMV immunotherapy.",
author = "Lim, {Jong Baeck} and Kwon, {Oh Hun} and Kim, {Hyon Suk} and Kim, {Hyun Ok} and Choi, {Jong Rak} and Maurizio Provenzano and David Stroncek",
year = "2004",
month = "6",
day = "30",
language = "English",
volume = "45",
pages = "18--22",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "SUPPL.",

}

Lim, JB, Kwon, OH, Kim, HS, Kim, HO, Choi, JR, Provenzano, M & Stroncek, D 2004, 'Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients', Yonsei medical journal, vol. 45, no. SUPPL., pp. 18-22.

Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients. / Lim, Jong Baeck; Kwon, Oh Hun; Kim, Hyon Suk; Kim, Hyun Ok; Choi, Jong Rak; Provenzano, Maurizio; Stroncek, David.

In: Yonsei medical journal, Vol. 45, No. SUPPL., 30.06.2004, p. 18-22.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients

AU - Lim, Jong Baeck

AU - Kwon, Oh Hun

AU - Kim, Hyon Suk

AU - Kim, Hyun Ok

AU - Choi, Jong Rak

AU - Provenzano, Maurizio

AU - Stroncek, David

PY - 2004/6/30

Y1 - 2004/6/30

N2 - Cytomegalovirus (CMV) reactivation in immune compromised patients such as those undergoing hematopoietic progenitor cell transplantation (HPCT) and those with HIV infections can cause severe morbidity and mortality despite treatment with appropriate antiviral agents. The recovery of Cytomegalovirus (CW) specific cytotoxic T lymphocytes (CTL) plays an important role in the reconstitution of CMV specific immunity in immunocompromised patients. Recent studies have reported that CMV reactivation can be successfully treated by adoptive transfer of CW-specific T cell clones from CMV seropositive donors expanded in vitro with CMV infected fibroblasts or lysates of CMV infected cells. Other studies have used immune dominant CMV proteins or peptides to expand CMV-specific cytotoxic T lymphocytes. This review describes the clinical manifestations of CMV disease in immunocompromised patients, recent advances of antiviral therapy for CMV disease, the principals of the induction of cellular immune response to CMV, and the clinical application of CMV immunotherapy.

AB - Cytomegalovirus (CMV) reactivation in immune compromised patients such as those undergoing hematopoietic progenitor cell transplantation (HPCT) and those with HIV infections can cause severe morbidity and mortality despite treatment with appropriate antiviral agents. The recovery of Cytomegalovirus (CW) specific cytotoxic T lymphocytes (CTL) plays an important role in the reconstitution of CMV specific immunity in immunocompromised patients. Recent studies have reported that CMV reactivation can be successfully treated by adoptive transfer of CW-specific T cell clones from CMV seropositive donors expanded in vitro with CMV infected fibroblasts or lysates of CMV infected cells. Other studies have used immune dominant CMV proteins or peptides to expand CMV-specific cytotoxic T lymphocytes. This review describes the clinical manifestations of CMV disease in immunocompromised patients, recent advances of antiviral therapy for CMV disease, the principals of the induction of cellular immune response to CMV, and the clinical application of CMV immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=3543028620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543028620&partnerID=8YFLogxK

M3 - Review article

C2 - 15250045

AN - SCOPUS:3543028620

VL - 45

SP - 18

EP - 22

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - SUPPL.

ER -

Lim JB, Kwon OH, Kim HS, Kim HO, Choi JR, Provenzano M et al. Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients. Yonsei medical journal. 2004 Jun 30;45(SUPPL.):18-22.